Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Noémi Roy was awarded an Academy of Medical Sciences Starter Grant for Clinical Lecturers.  These grants are aimed at supporting Clinical Lecturers in strengthening their research experience at post-doctoral level.  Noémi will be working in Veronica Buckle’s lab, studying the phenotype of a CDAN1 conditional knock-out mouse in the haematopoietic system.  CDAN1 is one of the genes known to cause Congenital Dyserythropoietic Anaemia.
 

noemi_roy

 

Similar stories

Hashem Koohy receives Turing Fellowship

Fellows are established scholars with proven research excellence in data science, artificial intelligence (AI), or a related field.

New atlas revealed of bone marrow haematopoiesis during development

A new study published this week in Nature, provides the most detailed analysis so far of the prenatal development of blood and immune cells in the bone marrow.

Changes in blood cell production over the human lifetime may hold clues to patterns of disease

A new paper published in Cell Reports reveals that changes in the gene expression of blood stem cells occur across the human lifetime; an important step in the understanding and treatment of blood disorders.

New Associate Professor appointments announced

Congratulations to Dr Bethan Psaila, Dr Benjamin Fairfax, Dr Hashem Koohy, Dr Andrew Blackford and Dr Oliver Bannard who have all been awarded the title of Associate Professor in recognition of their research achievements, contribution to teaching and contributions to the Medical Sciences Division.

Mechanism behind repair of cancer-inducing mutations discovered

New Nature paper uncovers the precise mechanism behind how the BRCA1 protein detects and engages with DNA breaks in the genome, helping to prevent the development of breast and ovarian cancers.